GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE
ConditionInfluenza
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-55
SponsorImperial College London
About this trial
This experimental medicine study aims to compare immune responses in healthy adult volunteers aged 18-55 years against influenza vaccination and infection in the upper and lower respiratory tract, following administration of a live-attenuated influenza vaccine delivered by nasal spray versus influenza A (H3N2) viral challenge.
Eligibility criteria
Qualifiers
Adults aged between 18-55 years inclusive
Sero-suitable as defined by a serum micro-neutralisation titre <1:20
Female participant who is not of child-bearing potential as assessed by an investigator OR is willing and able to use contraception as described in the protocol
Male participants who are willing to use one of the contraception methods described in the protocol
Disqualifiers
History of clinically significant/currently active conditions;
Cardiovascular, thromboembolic/cerebrovascular disease.
Types of chronic respiratory disease in adulthood.
Significant wheeze in the past
Trial design
Treatments tested in this trial
- FLUENZ
- Influenza challenge virus
Treatment groups
36 Participants
are divided into 2 treatment groupsSponsors and collaborators
Imperial College London
Lead sponsor
Imperial College Healthcare NHS Trust
Collaborator
Source ClinicalTrials.gov